The Role of the Suprachoroidal Space in the Treatment of UME and Other Retinal Diseases (CME Monograph)

Activity Description and Purpose

Current strategies for treatment of posterior segment diseases rely on diffusion of molecules across multiple tissues to reach their intended target. Safer and more targeted therapy remains an important unmet need. Novel treatments and methods of administration seek to use the suprachoroidal space (SCS) as a potentially safer and more effective route of drug delivery to treat uveitic macular edema (UME) and other posterior segment diseases with inflammatory components. In this educational activity, an expert panel will discuss the challenges of current management strategies for inflammatory posterior segment diseases, present the SCS as a novel and promising route of drug delivery, and review data from recent clinical trials. The desired results of this educational activity are to help retina specialists and comprehensive ophthalmologists understand the clinical trial data of emerging agents for posterior segment diseases targeting the SCS, including how to appropriately inject into the SCS.

Target Audience

This educational activity is intended for retina specialists and comprehensive ophthalmologists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Appraise routes for delivery of drugs for UME and retinal vascular diseases
  • Describe the potential role of the SCS as a delivery target in the treatment of UME and other retinal diseases
  • Interpret clinically relevant data on emerging therapies delivered via the SCS in patients with UME and other retinal diseases
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Course opens: 
Course expires: 


Quan Dong Nguyen, MD, MSc (Chair)
Professor of Ophthalmology
Byers Eye Institute
Stanford University School of Medicine
Palo Alto, California

Peter K. Kaiser, MD
Chaney Family Endowed Chair in Ophthalmology Research
Professor of Ophthalmology
Cole Eye Institute
Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio

Pauline T. Merrill, MD
Associate Professor of Ophthalmology
Rush University Medical Center
Illinois Retina Associates
Chicago, Illinois

Steven Yeh, MD
Associate Professor of Ophthalmology
Director, Section of Uveitis and Vasculitis
Emory University School of Medicine
Atlanta, Georgia

Disclosure Policy

MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.


Peter K. Kaiser, MD, is a consultant for Aerie Pharmaceuticals, Inc, Alcon, Allegro Ophthalmics, LLC, Allergan, Alzheon, Inc, Annexon Inc, AsclepiX, Bausch & Lomb Incorporated, Bayer Corporation, Bioeq GmbH, Biogen Idec, Bionic Vision Technologies, Boehringer Ingelheim International GmbH, Carl Zeiss Meditec, Inc, Chengdu Kanghong Pharmaceutical Group Co Ltd, Clearside Biomedical, Inc, DTx Pharma, Duet Therapeutics, Inc, Eyevensys, Formycon AG, Galecto Biotech, Galimedix Therapeutics, Inc, Gemini Therapeutics, Glaukos Corporation, Innovent Biologics, Inc, Irenix Medical, Inc, IVERIC bio, jCyte, Kala Pharmaceuticals, Kanaph Therapeutics, Kodiak Sciences Inc, NGM Biopharmaceuticals, Novartis Pharmaceuticals Corporation, Ocugenix, Oculis, Ocuphire Pharma, OcuTerra Therapeutics, Omeros Corporation, Opthea, Oxurion NV, Palatin Technologies, Inc, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, Retinal Sciences, Retrotope Inc, Roivant Sciences Ltd, Sandoz International GmbH, Santen Inc, Spark Therapeutics, Inc, Stealth BioTherapeutics Inc, Sustained Nano Systems, LLC, Takeda Pharmaceuticals USA, Inc, and Théa Pharmaceuticals Limited; is on the speakers bureau for Novartis Pharmaceuticals Corporation; and has ownership interest (future stock options) in Allegro Ophthalmics, LLC, and IVERIC bio.

Pauline T. Merrill, MD, is a consultant for Gilead and Santen Inc; is a contracted researcher for Gilead and Santen Inc; and has ownership interest (stocks) in Covalent Medical LLC.

Quan Dong Nguyen, MD, MSc, is a consultant for Bausch & Lomb Incorporated, EyePoint Pharmaceuticals, Mallinckrodt, and Regeneron Pharmaceuticals, Inc.

Steven Yeh, MD, is a consultant for Adverum, Bausch & Lomb Incorporated, and Regenxbio Inc.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant financial relationships.

Planners and Managers

MedEdicus planners and managers have no relevant commercial relationships to disclose.

Accreditation Statement

image MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from Bausch & Lomb Incorporated.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at


The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Bausch & Lomb Incorporated, or RETINA.

This CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 239

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Please login or register to take this course.

Clicking Register indicates that you have reviewed the CME information for this activity.